Drug Overview: Invokana

Drug Overview: Invokana

  • February 2018 •
  • 33 pages •
  • Report ID: 5391417 •
  • Format: PDF
Drug Overview
Invokana (canagliflozin; Johnson&Johnson/Mitsubishi Tanabe/Daiichi Sankyo) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class. SGLT-2 inhibitors do not target insulin secretion or sensitivity and do not interfere with glucose metabolism. They prevent filtered glucose from being reabsorbed in the kidney rather than actively facilitating glucose filtration and excretion. Due to this distinct mechanism of action, when SGLT-2 inhibitors are used as monotherapy they do not lower glucose to unsafe levels and thus avoid the risk of hypoglycemia.